These doses correspond to approximately 30, 40, and 0.5 times the recommended human daily inhalation dose (RHDID) on a mcg/m2 basis, respectively. Instruct patients that STIOLTO RESPIMAT inhalation spray should only be administered via the STIOLTO RESPIMAT inhaler and the STIOLTO RESPIMAT inhaler should not be used for administering other medications. When patients are prescribed STIOLTO RESPIMAT, other inhaled medications containing long-acting beta2-agonists should not be used.
Stiolto Respimat with certain urinary incontinence medications
- These trials included 5,162 adult COPD patients (72.9% males and 27.1% females) 40 years of age and older.
- STIOLTO RESPIMAT is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product see WARNINGS AND PRECAUTIONS.
- You use them when you need quick relief from COPD symptoms.
- COPD may deteriorate acutely over a period of hours or chronically over several days or longer.
- Here’s some detail on some of the side effects this drug may or may not cause.
The STIOLTO RESPIMAT inhaler is locked after the labeled number of puffs have been used. Is the dose indicator on the STIOLTO RESPIMAT pointing to 0 (zero)? Open the cap, press the dose-release button, then insert the cartridge. Any minor discoloration in the mouthpiece does not affect your STIOLTO RESPIMAT inhaler.
Is Your Medication Making You Tired?
Therefore, both medications can cause very similar side effects. You take Stiolto Respimat as two inhalations (puffs), once a day. Anoro contains the drugs umeclidinium and vilanterol.
Will I need to use this drug long term?
Other inhaled medicines, sometimes called rescue inhalers, should be used to treat sudden symptoms. Stiolto Respimat contains two medicines, tiotropium and olodaterol. Stiolto Respimat (tiotropium/olodaterol) is commonly used for chronic obstructive pulmonary disease (COPD), including emphysema and chronic bronchitis.
Recommended Dosage
The effect of olodaterol on the QT/QTc interval of the ECG was investigated in 24 healthy male and female volunteers in a double-blind, randomized, placebo- and active (moxifloxacin)- controlled study at single doses of 10, 20, 30, and 50 mcg. Subjects received tiotropium inhalation powder 18 mcg, 54 mcg (3 times the recommended dose), or placebo for 12 days. These drugs represent 2 different classes of medication (an anticholinergic and a beta-agonist) that have different effects on clinical and physiological indices. Dry mouth/throat and dry nasal mucosa occurred in a dose-dependent 10-40 mcg daily manner, were observed following 14-day dosing of up to 40 mcg tiotropium bromide inhalation solution in healthy subjects.
What is the dosage for Stiolto Respimat?
Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol see WARNINGS AND PRECAUTIONS. Tiotropium has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids, without increases in adverse reactions. These trials included 5,162 adult COPD patients (72.9% males and 27.1% females) 40 years of age and older.
Because of the potential for beta-agonist interference with uterine contractility, use of STIOLTO RESPIMAT during labor should be restricted to those patients in whom the benefits clearly outweigh the risks. There are no adequate and well-controlled human studies that have investigated the effects of STIOLTO RESPIMAT on preterm labor or labor at term. Olodaterol produced increased frequency of micronuclei in rats after intravenous doses. STIOLTO RESPIMAT patients are to actuate the inhaler toward the ground until an aerosol cloud is visible and then to repeat the process three more times.
Stiolto Respimat is a combination of inhaled medications tiotropium bromide and olodaterol prescribed to treat (COPD) chronic obstructive pulmonary disease. The recommended dose is 2 oral inhalations once daily at the same time of day. In clinical trials the most frequent serious adverse effects reported were worsening of COPD and pneumonia.
Once you’ve put Stiolto Respimat together and it’s ready for use, follow these directions to take your dose. The cartridge contains the medication that you’ll breathe in through the inhaler. Before you use a new Stiolto Respimat inhaler for the first time, insert the cartridge into the inhaler. If you’ve already prepared your inhaler for first-time use, see the instructions in the “Using your inhaler” section below. If you’re using your inhaler for the first time, see the instructions in the “Preparing your inhaler for first-time use” section below.
Stiolto Respimat and theophylline
Stiolto Respimat is FDA-approved as a long-term, maintenance (everyday) treatment for chronic obstructive pulmonary disease (COPD). The Food and Drug Administration (FDA) approves prescription drugs such as Stiolto Respimat to treat certain conditions. You should always have a rescue inhaler with you, even if you take Stiolto Respimat every day. Stiolto Respimat is used once a day to help prevent COPD symptoms on a long-term basis. (Rescue drugs are used for sudden breathing problems.) In clinical studies, Stiolto Respimat improved certain aspects of lung function (how well lungs work) better than Spiriva.
As with most drugs, some people can have an allergic reaction after taking Stiolto Respimat. Here’s some detail on some of the side effects this drug may or may not cause. You may wonder how often certain side effects occur with this drug, or whether certain side effects pertain to it. Most of these side effects may go away within a few days or a couple of weeks.
Drug-drug interaction studies were carried out using fluconazole as a model inhibitor of CYP 2C9 and ketoconazole as a potent P-gp (and CYP3A4, 2C8, 2C9) inhibitor. An interaction study with tiotropium (14.4 mcg intravenous infusion over 15 minutes) and cimetidine 400 mg three times daily or ranitidine 300 mg once-daily was conducted. More than 90% of the dose was excreted within 6 and 5 days following intravenous and oral administration, respectively. This metabolite, however, is not detectable in plasma after chronic inhalation of the recommended therapeutic dose.
- Contact your healthcare provider right away if you develop these symptoms.
- This document does not contain all possible side effects and others may occur.
- This includes tiotropium, one of the active drugs in Stiolto Respimat.
- The increased bronchodilator effects of STIOLTO RESPIMAT compared to tiotropium 5 mcg and olodaterol 5 mcg were maintained throughout the 52-week treatment period.
- The STIOLTO RESPIMAT cartridge has a net fill weight of at least 4 grams and when used with the STIOLTO RESPIMAT inhaler, is designed to deliver the labeled number of metered actuations after preparation for use.
It is important for patients to understand how to pin up online casino correctly administer STIOLTO RESPIMAT inhalation spray using the STIOLTO RESPIMAT inhaler. Patients who have been taking inhaled, short-acting beta2-agonists on a regular basis should be instructed to discontinue the regular use of these products and use them only for the symptomatic relief of acute symptoms. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist such as albuterol.
Enrolled patients (3,939 patients receiving STIOLTO RESPIMAT and 3,941 patients receiving tiotropium 5 mcg inhalation spray) had a history of COPD exacerbation in the previous 12 months. Patients treated with STIOLTO RESPIMAT used less rescue medication compared to patients treated with tiotropium 5 mcg and olodaterol 5 mcg. The efficacy of STIOLTO RESPIMAT is based primarily on two 4-week dose-ranging trials in 592 COPD patients and two confirmatory active-controlled 52-week trials (Trials 1 and 2) in 5,162 COPD patients.
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of olodaterol, one component of STIOLTO RESPIMAT, may be potentiated see WARNINGS AND PRECAUTIONS. In a one year trial (Trial 5) of 7,880 patients to compare rates of COPD exacerbations, 3,939 patients were treated with STIOLTO RESPIMAT and 3,941 patients were treated with tiotropium 5 mcg inhalation spray. The proportion of patients who discontinued due to an adverse reaction was 7.4% for STIOLTO RESPIMAT treated patients compared to 9.9% and 9.0% for olodaterol 5 mcg and tiotropium 5 mcg treated patients. Each actuation from the STIOLTO RESPIMAT inhaler delivers 2.5 mcg tiotropium (equivalent to 3.124 mcg tiotropium bromide monohydrate) and 2.5 mcg olodaterol (equivalent to 2.736 mcg olodaterol hydrochloride) from the mouthpiece. STIOLTO RESPIMAT is a combination of tiotropium bromide and olodaterol indicated for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STIOLTO RESPIMAT is a combination of tiotropium, an anticholinergic, and olodaterol, a long-acting beta2-adrenergic agonist (LABA).
The terminal half-life following inhalation in contrast is about 45 hours, indicating that the latter is determined by absorption rather than by elimination processes. Total clearance of olodaterol in healthy volunteers is 872 mL/min, and renal clearance is 173 mL/min. The renal clearance of tiotropium exceeds the creatinine clearance, indicating secretion into the urine.
The maximum mean (one-sided 95% upper confidence bound) difference in QTcI from placebo after baseline correction was 2.5 (5.6) ms, 6.1 (9.2) ms, 7.5 (10.7) ms, and 8.5 (11.6) ms following doses of 10, 20, 30, and 50 mcg, respectively. Relative to placebo, the maximum mean change from baseline in study-specific QTc interval was 3.2 msec and 0.8 msec for tiotropium inhalation powder 18 mcg and 54 mcg, respectively. In vitro studies have shown that olodaterol has 241-fold greater agonist activity at beta2-adrenoceptors compared to beta-adrenoceptors and 2,299-fold greater agonist activity compared to beta3-adrenoceptors. The compound exerts its pharmacological effects by binding and activation of beta2-adrenoceptors after topical administration by inhalation.
Both drugs contain a long-acting beta2-agonist (LABA) and a long-acting anticholinergic (LAMA). Stiolto Respimat contains the drugs tiotropium and olodaterol. These drugs haven’t been directly compared in clinical studies. Both drugs are used as long-term maintenance (everyday) treatment of COPD and are taken once a day.
Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to STIOLTO RESPIMAT. When prescribing STIOLTO RESPIMAT, the healthcare provider should also prescribe an inhaled, short-acting beta2-agonist and instruct the patient on how it should be used. STIOLTO RESPIMAT should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm.